Volume 30, Number 6—June 2024
Dispatch
Invasive Pulmonary Aspergillosis in Critically Ill Patients with Hantavirus Infection, Austria
Stefan Hatzl, Laura Scholz, Florian Posch, Philipp Eller, Alexander C. Reisinger, Martin Zacharias, Gregor Gorkiewicz, Martin Hoenigl, Ines Zollner-Schwetz, and Robert Krause
Table 1
Baseline characteristics of 29 hantavirus patients hospitalized in ICU, Graz, Austria*
| Characteristic | Value |
|---|---|
| Age, y (range) |
51 (44–65) |
| Sex | |
| F | 5 (17) |
| M |
24 (83) |
| BMI, kg/m2 |
26.2 (24.1–28.1) |
| Known contact with rodents or rodent excreta |
17 (59) |
| Concurrent conditions | |
| Hypertension | 8 (27) |
| Diabetes mellitus | 1 (4) |
| Atrial fibrillation | 2 (8) |
| Thromboembolic disease | 4 (13) |
| COPD | 2 (7) |
| Asthma | 2 (8) |
| Prior cancer in remission |
1 (34) |
| Signs and symptoms at diagnosis | |
| Headache | 21 (72) |
| Eye pain | 2 (7) |
| Fever >38.5°C (101.3°F) | 29 (100) |
| Body temperature, °C (range) | 39.5 (39.2–40.1) |
| Diarrhea | 13 (45) |
| Abdominal pain | 11 (38) |
| Kidney pain | 3 (10) |
| Blurred vision | 2 (8) |
| Time from first symptom to diagnosis, d |
3 (1–4) |
| Median blood counts at diagnosis (range) | |
| Leukocytes, G/L | 10.2 (6.9−14.7) |
| Neutrophils, G/L | 8.2 (5.5−12.5) |
| Lymphocytes, G/L | 0.7 (0.6–0.9) |
| Hemoglobin, g/dL | 15.2 (11.4–17.5) |
| Platelets, G/L |
58 (33–74) |
| Median laboratory results at diagnosis (range) | |
| Creatinine, mg/dL | 4.2 (1.6–6.6) |
| eGFR, mL/min | 16.3 (8.0–40.9) |
| Urea, mg/dL | 117 (69−178) |
| C-reactive protein, mg/L | 131 (95−176) |
| PCT, mg/L | 8.5 (2.6−19.5) |
| Interleukin-6, pg/mL | 151 (56–410) |
| Bilirubin, mg/dL | 0.59 (0.5–0.8) |
| AST, U/L | 46 (30–99) |
| ALT, U/L | 46 (26–135) |
| LDH, U/L |
390 (271–696) |
| Median coagulation test results (range) | |
| Prothrombin time, % | 90 (65–98) |
| aPTT, s | 41.0 (36.1–49.1) |
| D-Dimer, mg/L |
11.5 (3.8−15.9) |
| ICU characteristics | |
| SOFA | 10 (range 7–15) |
| paO2/FiO2 ratio | 150 (range 97–188) |
| Oxygen supply | |
| None | 2 (8) |
| Mask | 7 (25) |
| HFNC | 2 (8) |
| NIV-CPAP | 10 (29) |
| Mandatory ventilation | 9 (31) |
| vvECMO | 2 (8) |
| vaECMO | 1 (4) |
| Need for dialysis/hemofiltration | 19 (66) |
| Need for vasopressors | 14 (48) |
| Low-dose | 10 (72) |
| High-dose |
4 (28) |
| Outcomes | |
| Proportion of HAPA | 2 (6.9) |
| Deceased | 5 (17) |
| Length of ICU stay, d (range) | 4.5 (2.8−10.3) |
| Length of hospital stay, d (range) | 13.0 (9.0–28.0) |
*Values are no. (%) except as indicated. ALT, alanine aminotransferase; aPTT, activated prothrombin time; AST, aspartate aminotransferase; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HFNC, high-flow nasal cannula; ICU, intensive care unit; LDH, lactate dehydrogenase; NIV-CPAP, noninvasive ventilation continuous positive airway pressure; SOFA, sequential organ failure assessment; vaECMO, venoarterial extracorporeal membrane oxygenation; vvECMO veno-venous extracorporeal membrane oxygenation.
Page created: May 09, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.